Tonix Pharmaceuticals
TNXP
$19.64 0.56%
Exchange: NASDAQ | Sector: Healthcare | Industry: Biotechnology
Q3 2024
Published: Nov 12, 2024

Earnings Highlights

  • Revenue of $2.82M down 29.3% year-over-year
  • EPS of $-0.23 increased by 99.6% from previous year
  • Gross margin of 44.9%
  • Net income of -14.21M
  • "We believe TNX1500 has the potential to uniquely address significant unmet needs within transplantation medicine." - CEO of Tonix Pharmaceuticals
TNXP
Tonix Pharmaceuticals Holding Corp

Executive Summary

In Q3 2024, Tonix Pharmaceuticals Holding Corp (TNXP) reported revenues of $2.82 million, representing a 27.81% quarter-over-quarter increase. However, this is a decline of 29.26% year-over-year, reflecting ongoing challenges in their operational execution amidst a highly competitive biotechnology environment. The company reported a net loss of $14.21 million, which is a slight improvement in terms of net income margin from the previous quarter. With a focus on expanding their therapeutic portfolio, particularly in immunology and CNS markets, management is optimistic about future revenue generation potential. Their cash position remains solid with $28.23 million in cash and equivalents at quarter-end.

Key Performance Indicators

Revenue
Decreasing
2.82M
QoQ: 27.81% | YoY: -29.26%
Gross Profit
Decreasing
1.27M
44.90% margin
QoQ: 209.32% | YoY: -21.55%
Operating Income
Increasing
-15.55M
QoQ: 15.28% | YoY: 44.74%
Net Income
Increasing
-14.21M
QoQ: 81.96% | YoY: 49.19%
EPS
Increasing
-0.23
QoQ: 98.81% | YoY: 99.61%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q4 2024 2.58 -976.72 -31.7% View
Q3 2024 2.82 -0.23 -29.3% View
Q2 2024 2.21 -19.28 +0.0% View
Q1 2024 2.48 -5.91 -92.7% View
Q4 2023 3.78 -27.53 +0.0% View